‘Chemobrain’: Neuroimmunological Consequences Of Chemotherapy-induced Mucositis And Opioid Palliation In Development Of The Condition
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Approximately 46% of cancer patients receiving chemotherapy will experience cognitive impairment. The development of this condition may be linked to another common gut side-effect of chemotherapy- mucositis. The treatment of mucositis pain by potent painkillers called opioids may also increase the risk of cognitive change. This project will determine the nervous system changes occurring in mucositis to identify targets for drug intervention to prevent development of cognitive decline.
Interleukin-6 -gp130 Signaling And Actions In The CNS
Funder
National Health and Medical Research Council
Funding Amount
$549,092.00
Summary
Interleukin-6 (IL-6) is a member of a family of cytokine proteins that may be causative factors in many neurological disorders where they are involved in diverse processes including inflammation, neuronal injury and repair. In this project we will study how IL-6 affects the brain to bring about these outcomes. The results of this work will advance our understanding of how members of this cytokine family function and how they contribute to neurological disease.
The Contribution Of IL-1 Signalling To Long-term Neurodegeneration, Epilepsy And Neurocognitive Outcomes Following Traumatic Injury To The Paediatric Brain
Funder
National Health and Medical Research Council
Funding Amount
$394,670.00
Summary
Epilepsy is a common, debilitating consequence of brain injury in children, however little is known about factors which trigger its development. This proposal investigates the contribution of the acute inflammatory response to long-term neuronal loss, functional outcomes and seizure activity after paediatric brain injury. Understanding how epilepsy and brain damage progresses after injury will aid the development of drugs to improve long-term outcomes in brain-injured children.